| Exelixis, Inc. Q1 2010 Earnings Call Transcript Exelixis, Inc. (EXEL)Q1 2010 Earnings Call TranscriptMay 11, 2010 5:00 pm ETComplete Story » seekingalpha.com |
Axial Capital Again Adds to QLT Stake Market Folly submits:Just a few days ago we detailed how Eliav Assouline and Marc Andersen's hedge fund Axial Capital was buying shares of QLT Inc (QLTI). This trend continues as Axial recently filed another Form 4 with the SEC regarding QLTI shares. On July 6th, 2010, Axial purchased 109,157 shares of QLT Inc. at a price of $5.79 per share. This brings their total ownership up to 6,304,586 shares. Eliav and Andersen's hedge fund has been accumulating shares over the span of a few months now, continuing to buy as QLTI trades lower.The interesting thing with this play is that many have characterized QLT Inc as a value trap or a 'cigarette-butt' type of investment. It is essentially a play on the biotech company's royalty stream. Some argue that while the stream is healthy now, it is likely to decline. Assouline and Andersen seem to disagree as they continue to accumulate shares.Complete Story » seekingalpha.com |
Generex: Reverse Split Not Approved Thomas Barnard submits:Funding for the development companies that I have followed over the years always have their problems. While the product is being developed, which can take five or ten or fifteen years, the managers have the job of continuing to find funding for the development.Unfortunately for investors, this process usually sees stock prices in continual decline. Generex is no exception to this. Shares have been sold to new large investors in ever declining prices.Complete Story » seekingalpha.com |
WellPoint Unit to Reimburse Policyholders A WellPoint subsidiary in Colorado agreed to repay policyholders in that state $20 million after an examination by the state insurance commissioner concluded that several premium increases were unjustified. online.wsj.com |
Forest Labs Sees Large Call Selling optionMONSTER submits: By Chris McKhann Forest Laboratories (FRX) has climbed to a new two-year high, but the big trade so far today is someone selling the upside in the pharmaceutical company. Complete Story » seekingalpha.com |